Core Points - Grupo Aeroportuario del Pacífico (GAP) has completed the ordinary review process for maximum tariffs per passenger and committed investments for Kingston Airport for the 2026-2030 period [1] - The maximum passenger charges for Kingston Airport will increase from $38.18 in 2026 to $60.10 in 2030 [1] - The total committed investments under the Capital Development Program for Kingston Airport amount to $85.2 million, with scheduled investments of $45.8 million in 2026, $23.4 million in 2028, and smaller amounts in other years [1] Company Overview - Grupo Aeroportuario del Pacífico operates 12 airports in Mexico's Pacific region, including major cities like Guadalajara and Tijuana, and tourist destinations such as Puerto Vallarta and Los Cabos [2] - The company was listed on the New York Stock Exchange in February 2006 and on the Mexican Stock Exchange [2] - GAP acquired a majority stake in MBJ Airports Limited in April 2015 and entered into a concession agreement for Norman Manley International Airport in Kingston, Jamaica, in October 2018 [2]

Core Viewpoint - Panther Minerals Inc. has successfully completed a debt settlement agreement to address outstanding debts totaling CAD $14,785.71, enhancing its cash position for working capital purposes [1][2]. Group 1: Debt Settlement Details - The company issued 924,106 common shares at a deemed price of CAD $0.016 per share as part of the debt settlement [1]. - The shares issued are subject to a hold period of four months and one day, in accordance with National Instrument 45-105 – Prospectus Exemptions [1]. Group 2: Company Overview - Panther Minerals is engaged in mineral exploration, focusing on its North American project portfolio [3]. - The acquisition of the Boulder Creek option demonstrates the company's commitment to pursuing advanced and high-quality uranium projects that can be efficiently explored [3].

Core Viewpoint - Asante Gold Corporation reported significant operational progress and financial results for Q1 2026, with expectations for continued growth and production increases in the coming years [3][5][14]. Financial Results - Revenue for Q1 2026 was $141.98 million, a 24% increase from $114.31 million in Q1 2025, driven by higher gold prices despite a lower volume of gold sold [4][5]. - Total comprehensive loss for the quarter was $(20.04) million, compared to $(16.04) million in the same period last year [4]. - Adjusted EBITDA rose to $30.66 million from $13.03 million year-over-year, reflecting the impact of high gold prices [6]. Operational Results - Gold equivalent production was 51,912 ounces, down from 53,379 ounces in the same quarter of the previous year, attributed to lower feed grades at the Bibiani mine [7][11]. - The average gold price realized per ounce was $2,946, compared to $2,133 in the same period last year [5]. - All-in sustaining costs (AISC) increased by 58% to $2,971 per ounce, primarily due to increased stripping costs and lower grade ore [8][12]. Bibiani Mine Performance - Total material mined at Bibiani increased by 291.4% to 11,970 kt, while ore mined decreased by 4.8% to 558 kt [9][10]. - The strip ratio at Bibiani was 20.5:1, significantly higher than 4.2:1 in the previous year, reflecting the company's strategy to reduce waste stripping backlog [9][10]. - Revenue from Bibiani was $46.67 million, up from $41.31 million year-over-year, with an average gold price realized of $2,794 per ounce [9]. Chirano Mine Performance - Revenue for the Chirano mine was $95.31 million, an increase from $73.00 million in the same quarter of 2024 [15]. - Gold equivalent production was 34,671 ounces, slightly up from 34,196 ounces year-over-year, despite a decrease in ore grade processed [19]. - AISC for Chirano increased to $2,587 per ounce from $1,951 per ounce, driven by higher sustaining capital expenditures [20]. Future Outlook - The company plans to produce between 155,000 and 175,000 gold ounces at both Bibiani and Chirano for the year ending January 31, 2026, with significant production increases expected in the latter part of the fiscal year [14][21]. - The commissioning of the sulphide treatment plant is anticipated to enhance gold recovery and is expected to be fully operational by Q3 2026 [13][14].

Group 1: Job Market Overview - U.S. employers added 139,000 jobs in May, exceeding economists' expectations of 125,000-130,000, while the unemployment rate remained steady at 4.2% [1] - Job growth was strongest in the healthcare and leisure/hospitality sectors, which added 62,000 and 48,000 jobs, respectively [9] Group 2: Wage Growth and Inflation - Average hourly earnings rose 3.9% year over year, outpacing April's inflation rate of 2.3% [2] Group 3: Investment Opportunities - Paylocity (PCTY) has consistently surpassed earnings expectations, beating EPS estimates for its fiscal third quarter by 16% in May, with an average EPS surprise of 15.4% over the last four quarters [4] - Maximus (MMS) is experiencing rising EPS revisions and trades at a forward earnings multiple of 10.8X, with fiscal 2025 and FY26 EPS estimates rising nearly 7% and 4% in the last 30 days [5][7] - Other payroll stocks to consider include Dayforce (DAY) and Paychex (PAYX), along with Barrett Business Services (BBSI), all holding a Zacks Rank 3 (Hold) [8]

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc. and was filed in the District of Massachusetts [1]. - Investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, have until June 16, 2025, to seek lead plaintiff status [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. Group 2: Financial Impact - Zenas BioPharma sold over 13 million shares at $17.00 per share during its IPO [2]. - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, representing a 48.7% decline from the IPO price [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing the investors in the class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - A class action has been filed against Fortrea Holdings, Inc. for allegedly misleading investors regarding the progress of its pre-spin projects and financial expectations [1][2][4]. Group 1: Company Background - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides biopharmaceutical product and medical device development solutions [1]. - The company was spun off from Labcorp Holdings Inc. in June 2023 and operates under several transition services agreements with Labcorp [2]. Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA trajectories for 2025 were not in line with prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [3]. - The company indicated that its pre-spin projects were late in their life cycle, resulting in lower revenue and profitability than expected for 2025 [3]. Group 3: Allegations and Misstatements - The complaint alleges that Fortrea overestimated the revenue contributions from pre-spin projects and overstated potential cost savings from exiting transition services agreements [4]. - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, which misrepresented the viability of its post-spin business model and financial prospects [4].

Core Insights - Dollar General's share price increased by nearly 17% during the trading week following a strong earnings report [1] - The company reported net sales of $10.4 billion, a year-over-year increase of over 5%, driven by a 2% rise in same-store sales [4] - GAAP net income rose almost 8% to just under $392 million, translating to earnings of $1.78 per share [4] Financial Performance - Dollar General's earnings exceeded consensus analyst estimates, which were $10.25 billion for net sales and $1.46 per share for net income [5] - Analysts have responded positively, with several raising their price targets and upgrading their recommendations for the stock [5][6] Market Position and Outlook - Analysts, including Oppenheimer's Rupesh Parikh, view Dollar General as a strong performer, particularly in a recessionary environment, and have upgraded its rating to "overperform" [6][7] - The company is perceived as a potential go-to retailer amid economic uncertainty, making it a stock worth considering in the current market climate [8]

S&P Dow Jones Indices made no changes to the S&P 500 index on Friday, snubbing Robinhood (HOOD) and AppLovin (APP). The company made no announcement but confirmed to multiple publications that there were no additions or deletions to the benchmark index. It's the first quarterly rebalance without an S&P 500 stock change since March 2022. Analysts had pegged Robinhood stock… ...

Core Insights - Tesla's vice president of Optimus robotics, Milan Kovac, has announced his departure from the company after an eight-year tenure, expressing gratitude towards CEO Elon Musk and optimism for Tesla's future [1][2]. Company Developments - Tesla is developing the Optimus robot with plans to begin builds on its Fremont pilot production line in 2025, aiming for broader deployment of robots in factory settings [3]. - During the 2024 annual shareholder meeting, Musk projected that humanoid robots could significantly increase Tesla's market capitalization to $25 trillion at an unspecified future date [3]. Technological Advancements - Currently, Tesla is training its Optimus systems to perform basic tasks such as picking up objects, opening doors, and throwing balls, indicating progress in the development of the robot [4]. - Competitors in the robotics space include Boston Dynamics, Agility Robotics, Apptronik, 1X, and Figure, highlighting a competitive landscape for Tesla's Optimus initiative [4].

Group 1: Company Performance - Analog Devices (ADI) shares closed nearly 2% higher, outperforming the S&P 500 index which rose by just over 1% [1] - Citigroup identified Analog Devices as a top pick in the semiconductor sector, indicating confidence in its future performance [2] Group 2: Industry Insights - The semiconductor industry reported April sales of $55 billion, reflecting a decrease of more than 11% from March, but this was in line with seasonal trends and close to the forecasted 10% decline [4] - Year-over-year, April sales were 24% higher, indicating a positive long-term growth trajectory for the industry [4] - Average selling prices in April fell by 3.2% month over month, which was less than the anticipated 5.3% drop, suggesting a more stable pricing environment than expected [5] Group 3: Future Outlook - Citigroup forecasts an 8% increase in the semiconductor market over 2024's level, indicating a recovery and growth potential in the sector [6] - Analog Devices and Texas Instruments are viewed as defensive stocks, making them attractive picks in a challenging environment due to their wide product range, which provides a natural hedge [6]